Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

This double-blind, randomised, placebo-controlled trial (n=40) will investigate the persisting effects of a single dose of psilocybin (1-30mg) on structural plasticity in healthy older adults.

Researchers from the University of California, Berkeley aim to understand how psilocybin affects cognition, predictive coding, and affect in healthy older adults. They will compare baseline measurements to those taken one week and one month post-treatment.

Participants, aged 60-85, will be randomly assigned to receive a dose of psilocybin ranging from microdose to moderate-to-high dose, allowing for dose-response assessment. Brain imaging techniques such as MRI will be employed to evaluate changes in brain structure and activity, while cognitive exams and surveys will measure changes in cognition, predictive coding, and affect.

The study will provide insights into the potential therapeutic benefits of psilocybin for older adults, potentially informing treatments for conditions like Alzheimer’s disease. The trial is scheduled to begin in April 2025 and conclude in December 2027.

Trial Details



Trial Number

Sponsors & Collaborators

University of California Berkley
The UC Berkeley Center for the Science of Psychedelics (BCSP) is exploring psychedelics as tools for understanding the brain and mind, enhancing well-being, and deepening spirituality.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.